Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00026182
First received: November 9, 2001
Last updated: August 23, 2013
Last verified: August 2013

November 9, 2001
August 23, 2013
October 2001
February 2005   (final data collection date for primary outcome measure)
  • Objective response [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. In addition, confidence intervals for the response probability will be calculated according to the approach of Duffy and Santner.
  • Objective response [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
    The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. In addition, confidence intervals for the response probability will be calculated according to the approach of Duffy and Santner.
Not Provided
Complete list of historical versions of study NCT00026182 on ClinicalTrials.gov Archive Site
  • Overall response rate for MCL patients [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]
    Corresponding 95% confidence intervals will also be calculated.
  • Overall survival [ Time Frame: From randomization to death due to any cause, assessed up to 5 years ] [ Designated as safety issue: No ]
    The distribution this time measure will be estimated using the method of Kaplan-Meier.
  • Time to treatment failure [ Time Frame: From randomization to the treatment-specific definition of disease progression, death, or when the patient goes off study due to refusal or toxicity, assessed up to 5 years ] [ Designated as safety issue: No ]
    The distribution this time measure will be estimated using the method of Kaplan-Meier.
  • Complete response rate [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]
    Will be assessed and descriptively summarized.
  • Quality of life assessed using FACT-BRM [ Time Frame: Baseline ] [ Designated as safety issue: No ]
    Before and after treatment comparisons will be made using a paired samples t-test or its nonparametric equivalent. This two-sided test will have at least 80% power to detect a moderate effect size (0.42 times the standard deviation) in the FACT-BRM scores.
  • Quality of life assessed using FACT-BRM [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    Before and after treatment comparisons will be made using a paired samples t-test or its nonparametric equivalent. This two-sided test will have at least 80% power to detect a moderate effect size (0.42 times the standard deviation) in the FACT-BRM scores.
  • Quality of life assessed using FACT-BRM [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Before and after treatment comparisons will be made using a paired samples t-test or its nonparametric equivalent. This two-sided test will have at least 80% power to detect a moderate effect size (0.42 times the standard deviation) in the FACT-BRM scores.
Not Provided
Not Provided
Not Provided
 
Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
Randomized Phase II Study Of Interleukin-12 In Combination With Rituximab In Patients With Non-Hodgkin's Lymphoma

Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Interleukin-12 may kill cancer cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells. Combining rituximab with interleukin-12 may kill more cancer cells. This randomized phase II trial is comparing how well giving rituximab together with two different schedules of interleukin-12 works in treating patients with B-cell non-Hodgkin lymphoma.

OBJECTIVES:

I. Compare the objective response in patients with B-cell non-Hodgkin's lymphoma treated with rituximab and 2 different schedules of interleukin-12*.

II. Compare the toxic effects of these regimens in these patients. III. Determine the objective response rate in patients with mantle cell lymphoma treated with these regimens.

IV. Determine the overall and progression-free survival of patients treated with these regimens.

V, Compare the quality of life of patients treated with these regimens. NOTE: *Interleukin-12 will no longer be available after 6/30/05.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to histology (mantle cell lymphoma vs other [closed to accrual as of 3/10/04]) and International Prognostic Factor Index (low and low-intermediate risk [closed to accrual as of 3/10/04] vs high-intermediate and high risk). Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive rituximab IV on days 1, 8, 15, and 22. Patients receive interleukin-12* subcutaneously (SC) twice weekly beginning on day 2 and continuing until disease progression.

ARM II (closed to accrual as of 11/14/03): Patients receive rituximab as in arm I. Patients are evaluated at week 12. Patients with stable or progressive disease receive interleukin-12* SC twice weekly until disease progression or for 24 weeks. Patients with a complete or partial response after rituximab are monitored until disease progression and then begin interleukin-12 SC twice weekly until further disease progression.

NOTE: *Interleukin-12 will no longer be available after 06/30/05. Patients proceed to follow-up as outlined below.

Quality of life is assessed at baseline and at 3 and 6 months.

Patients are followed every 3 months for 1 year and then every 6 months for up to 4 years.

PROJECTED ACCRUAL: A total of 90 patients (45 per treatment arm [arm II closed to accrual as of 11/14/03]) will be accrued for this study within 3 years.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
  • Nodal Marginal Zone B-cell Lymphoma
  • Recurrent Grade 1 Follicular Lymphoma
  • Recurrent Grade 2 Follicular Lymphoma
  • Recurrent Mantle Cell Lymphoma
  • Recurrent Small Lymphocytic Lymphoma
  • Splenic Marginal Zone Lymphoma
  • Biological: rituximab
    Given IV
    Other Names:
    • IDEC-C2B8
    • IDEC-C2B8 monoclonal antibody
    • Mabthera
    • MOAB IDEC-C2B8
    • Rituxan
  • Biological: recombinant interleukin-12
    Given SC
    Other Names:
    • cytotoxic lymphocyte maturation factor
    • IL-12
    • interleukin-12
    • natural killer cell stimulatory factor
    • Ro 24-7472
  • Other: laboratory biomarker analysis
    Correlative studies
  • Other: questionnaire administration
    Ancillary studies
  • Procedure: quality-of-life assessment
    Ancillary studies
    Other Name: quality of life assessment
  • Experimental: Arm I (rituximab and recombinant interleukin-12)
    Patients receive rituximab IV on days 1, 8, 15, and 22. Patients receive interleukin-12 SC twice weekly beginning on day 2 and continuing until disease progression.
    Interventions:
    • Biological: rituximab
    • Biological: recombinant interleukin-12
    • Other: laboratory biomarker analysis
    • Other: questionnaire administration
    • Procedure: quality-of-life assessment
  • Experimental: Arm II (rituximab and recombinant interleukin-12)
    Patients receive rituximab as in arm I. Patients are evaluated at week 12. Patients with stable or progressive disease receive interleukin-12 SC twice weekly until disease progression or for 24 weeks. Patients with a complete or partial response after rituximab are monitored until disease progression and then begin interleukin-12 SC twice weekly until further disease progression.
    Interventions:
    • Biological: rituximab
    • Biological: recombinant interleukin-12
    • Other: laboratory biomarker analysis
    • Other: questionnaire administration
    • Procedure: quality-of-life assessment
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
99
Not Provided
February 2005   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically confirmed CD20-positive B-cell non-Hodgkin's lymphoma
  • Previously treated low-grade lymphoma considered incurable with standard therapy

    • Grade I or II follicular lymphoma*
    • Lymphoplasmacytic lymphoma*
    • Small lymphocytic lymphoma*
    • Nodal marginal zone lymphoma*
    • Extranodal marginal zone lymphoma of MALT type*
    • Splenic marginal zone lymphoma*
  • Previously treated mantle cell lymphoma allowed
  • Meets one of the following criteria for measurable disease:

    • Bidimensional diameter at least 1.5 cm by 1.5 cm on physical exam
    • At least 2 cm in one dimension by CT scan, MRI, or plain radiograph imaging
    • Palpable spleen at least 5 cm below the left costal margin
  • No CNS involvement by lymphoma
  • Performance status - ECOG 0-1
  • At least 12 weeks
  • Absolute neutrophil count ≥ 1,500/mm^3
  • Platelet count ≥ 75,000/mm^3
  • Hemoglobin ≥ 8 g/dL
  • Bilirubin ≤ 3 times upper limit of normal (ULN)
  • AST and ALT ≤ 3 times ULN
  • Alkaline phosphatase ≤ 3 times ULN
  • Creatinine ≤ 2 times ULN
  • No New York Heart Association class III or IV heart disease
  • No history of angina
  • No uncontrolled peptic ulcer disease
  • No uncontrolled infection
  • No other active malignancy
  • No autoimmune-related phenomena (e.g., antinuclear antibody less than 2 times ULN, rheumatoid factor less than 2 times ULN, and negative direct Coombs)
  • HIV negative
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • Prior stem cell transplantation allowed
  • More than 12 months since prior rituximab
  • No prior interleukin-12
  • No other concurrent immunotherapy
  • Recovered from prior chemotherapy
  • No concurrent chemotherapy
  • No concurrent steroid therapy
  • No concurrent radiotherapy
  • Any number of prior therapies allowed
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00026182
NCI-2012-01865, NCI-2012-01865, NCCTG-N0087, CDR0000068994, N0087, N0087, U10CA025224
Not Provided
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Not Provided
Principal Investigator: Stephen Ansell North Central Cancer Treatment Group
National Cancer Institute (NCI)
August 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP